Live Shareholder Q&A and industry events

22 September 2022

ValiRx PLC ("ValiRx" or the "Company")

Live Shareholder Q&A and industry events

Live Q&A: London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, invites shareholders to join the CEO, Suzy Dilly and Shareholder Representative, Adam Hargreaves in a Zoom webinar on 29 September 2022 at 1pm (UK).

Registration prior to the event is recommended to ensure all notifications about the webinar are received by participants. Please register in advance of the event at: https://us02web.zoom.us/webinar/register/WN_LnCNxEbBSMOjzzYMxddhLA.

These registration details will also be available on the ValiRx website (https://www.valirx.com/contact). The format will comprise a "fireside chat" between Dr Dilly and Professor Hargreaves by the Company with shareholders invited to submit their questions prior to the event, or to activate their webcam and speak directly to ask their additional questions during the session. A recording of the event will be available to view from the ValiRx website shortly after the event concludes.

Industry Events: ValiRx participants are registered to take part in the Bio-Europe partnering conference in October (in-person) and November 2022 (virtual), seeking new project opportunities and introducing our expanded team and pipeline to other industry participants.  Dr Dilly is also attending the BioTech Outsourcing Strategies conference in Manchester in November, where she is chairing a session of presentations.

The Directors of the Company take responsibility for this announcement.

*** ENDS ***

For more information, please contact:

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. 

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.